Nova Eye Medical Limited
ELXMF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 25.5% | 37% | 27.3% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 64.5% | 86.6% | 4.9% | -5.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -23% | -25.6% | -55.7% | -59% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -31% | -37.7% | -89.8% | -56% |
| EPS Diluted | -0.037 | -0.043 | -0.096 | -0.051 |
| % Growth | 15.1% | 54.9% | -89.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |